Omthera announces positive bioavailability data from Epanova study

Epanova increased EPA and DHA more than 5-Fold Compared to Lovaza After two weeks of dosing in 52 subjects on a low fat diet.

Additionally, Epanova increased steady state plasma levels of EPA plus DHA by 448%, compared to 90% for Lovaza., the company said.

Omthera co-founder and chief medical officer Michael Davidson said the results which confirm the superior bioavailability of Epanova over the leading prescription Omega-3 in the steady state.

"The data supports our view that Epanova may well become the new best in class prescription product for addressing the unmet clinical need for the management of hypertriglyceridemia," Davidson added.